Advertisement
Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
Shanghai-based pet food maker Fubei has filed an application for an initial public offering in Hong Kong.
The share-price surge came as promising cancer trial data overshadowed continuing scrutiny of China’s biotechnology sector by US lawmakers.
Hong Kong trading soars 536 per cent, firm says, while making no mention of US$61 million fine from China’s market watchdog.
Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.
Advertisement
China’s gold reserves have grown for 18 straight months, country’s central bank says.
The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.
EV giant pushes affordable autonomy with its system, aiming to make self-driving safer and accessible to mass-market consumers.
Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.
Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research.
Centaline attributes the positive mood to improving China-US relations, solid economic data and policies that encourage talent inflow.
‘From a valuation point of view, this is still an attractive moment,’ as new growth drivers emerge from China’s tech sector, analyst says.
Investors are piling money into AI technologies – but revenues still have a long way to catch up, Macquarie’s Viktor Shvets says.
‘Moderate’ upside is possible as investors ‘direct attention back to China somewhat’, assuming trade truce is extended, bank says.
METiS TechBio debuts on Hong Kong stock market as its CEO compares the drug design start-up to SpaceX for the pharmaceutical industry.
Company’s shares jump in Hong Kong and Shenzhen after tie-up that bolsters China’s growing drug innovation profile.
Tech-heavy index breaches the 3,900-point mark amid strong signals from Beijing that it is committed to chip self-sufficiency.
Global investors pile into city’s latest bond sale, with orders 7.6 times oversubscribed, backing its green finance ambitions.
City aims to broaden gold offerings and expand clearing and storage facilities to seize opportunities in the surging market.
AI-powered drug developer Metis TechBio leads group that includes developers of autonomous driving technology and industrial robots.
State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.
The future of treating brain diseases could lie in non-invasive technologies, according to Chongqing Haifu Medical Technology.
About 70 per cent of buyers were end users and 30 per cent investors, with mainland buyers accounting for about 20 per cent of the total.
Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?
The non-invasive BCI technology offers a safer alternative to surgery for some conditions, BrainCo partner Nyx He says.
AI, robotics and energy storage firms make up most of the record-high IPO pipeline in Hong Kong, says Chan.
Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.
Under pilot rules, at least 65 per cent of capital must come from institutional investors and foreign ownership is capped at 49 per cent.
Citic leads Asia-Pacific in fees in the first quarter as IPOs in Hong Kong and mainland China offset weaker debt and M&A activity.
Sovereign wealth funds from Singapore and Abu Dhabi join Chinese state capital as cross-border biotech licensing reaches record highs.
